Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2) (NCT06960577)

🧪 Interventions in This Study

• Durvalumab (DRUG)
• Methotrexate (DRUG)
• Vinblastine (DRUG)
• Doxorubicin (DRUG)
• Cisplatin (DRUG)
• Durvalumab (DRUG)
• Gemcitabine (DRUG)
• Cisplatin (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (59 Sites)

Showing the first 25 of 59 sites.

• Research Site — Chermside,
• Research Site — Elizabeth Vale,
• Research Site — Heidelberg,
• Research Site — Hong Kong,
• Research Site — Kogarah,
• Research Site — Macquarie University,
• Research Site — Murdoch,
• Research Site — Port Macquarie,
• Research Site — St Leonards,
• Research Site — Barretos,
• Research Site — Jaú,
• Research Site — Natal,
• Research Site — Porto Alegre,
• Research Site — Rio de Janeiro,
• Research Site — Santo André,
• Research Site — São José do Rio Preto,
• Research Site — São Paulo,
• Research Site — Hamilton, Ontario
• Research Site — London, Ontario
• Research Site — Ottawa, Ontario
• Research Site — Montreal, Quebec
• Research Site — Québec, Quebec
• Research Site — Sherbrooke, Quebec
• Research Site — Angers,
• Research Site — Angers,

📞 Contact the Study Coordinator

Phone: (877) 240-9479

Email: information.center@astrazeneca.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Urinary Bladder Neoplasms

• A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder — Loma Linda, California
• A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer — Tucson, Arizona
• A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) — Birmingham, Alabama
• Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) — Washington D.C., District of Columbia
• A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy — Tucson, Arizona
• A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) — Bakersfield, California

Explore by condition: All Urinary Bladder Neoplasms clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.